Napoleone Ferrara and the saga of vascular endothelial growth factor
- PMID:18568940
- DOI: 10.1080/10623320802092377
Napoleone Ferrara and the saga of vascular endothelial growth factor
Abstract
Napoleone Ferrara and his colleagues at Genentech were the first to isolate and clone vascular endothelial growth factor (VEGF) in 1989. His laboratory has investigated many aspects of VEGF biochemistry and molecular biology. In 1993, Ferrara reported that inhibition of VEGF-induced angiogenesis by specific monoclonal antibodies resulted in dramatic suppression of the growth of a variety of tumors in vivo. These findings provided an important evidence that inhibition of angiogenesis may suppress tumor growth and blocking VEGF action could have therapeutic value for a variety of malignancies and validate the notion introduced in 1971 by Judah Folkman that inhibition of tumor angiogenesis might be a valid approach to control tumor growth. A further development was the design in a rational fashion in 1997 of a humanized anti-VEGF monoclonal antibody (Avastin), now in clinical trials as a treatment for several solid tumors and also outside of cancer, for example, in the treatment of age-related macular degeneration.
Similar articles
- From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti.Ferrara N.Ferrara N.Int J Dev Biol. 2011;55(4-5):383-8. doi: 10.1387/ijdb.103216dr.Int J Dev Biol. 2011.PMID:21858763
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.Ferrara N, Hillan KJ, Novotny W.Ferrara N, et al.Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35. doi: 10.1016/j.bbrc.2005.05.132.Biochem Biophys Res Commun. 2005.PMID:15961063Review.
- How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy.Blagosklonny MV.Blagosklonny MV.Cancer Biol Ther. 2005 Dec;4(12):1307-10. doi: 10.4161/cbt.4.12.2315. Epub 2005 Dec 11.Cancer Biol Ther. 2005.PMID:16322683Review.
- Clinical application of therapies targeting VEGF.Yancopoulos GD.Yancopoulos GD.Cell. 2010 Oct 1;143(1):13-6. doi: 10.1016/j.cell.2010.09.028.Cell. 2010.PMID:20887885
- Therapeutic anti-VEGF antibodies.Lien S, Lowman HB.Lien S, et al.Handb Exp Pharmacol. 2008;(181):131-50. doi: 10.1007/978-3-540-73259-4_6.Handb Exp Pharmacol. 2008.PMID:18071944Review.
Cited by
- Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis.Somanath PR, Malinin NL, Byzova TV.Somanath PR, et al.Angiogenesis. 2009;12(2):177-85. doi: 10.1007/s10456-009-9141-9. Epub 2009 Mar 8.Angiogenesis. 2009.PMID:19267251Free PMC article.Review.
- Recent Advances in Age-Related Macular Degeneration Therapies.Fabre M, Mateo L, Lamaa D, Baillif S, Pagès G, Demange L, Ronco C, Benhida R.Fabre M, et al.Molecules. 2022 Aug 10;27(16):5089. doi: 10.3390/molecules27165089.Molecules. 2022.PMID:36014339Free PMC article.Review.
- "Therapeutic advancements in nanomedicine: The multifaceted roles of silver nanoparticles".K Karunakar K, Cheriyan BV, R K, M G, B A.K Karunakar K, et al.Biotechnol Notes. 2024 Jun 1;5:64-79. doi: 10.1016/j.biotno.2024.05.002. eCollection 2024.Biotechnol Notes. 2024.PMID:39416696Free PMC article.Review.
- A robust model for simultaneously inducing corneal neovascularization and retinal gliosis in the mouse eye.Paranthan RR, Bargagna-Mohan P, Lau DL, Mohan R.Paranthan RR, et al.Mol Vis. 2011;17:1901-8. Epub 2011 Jul 14.Mol Vis. 2011.PMID:21850164Free PMC article.
- Regulatory effect of N6-methyladenosine on tumor angiogenesis.YuYan, Yuan E.YuYan, et al.Front Immunol. 2024 Sep 4;15:1453774. doi: 10.3389/fimmu.2024.1453774. eCollection 2024.Front Immunol. 2024.PMID:39295872Free PMC article.Review.
Publication types
MeSH terms
Substances
Personal name as subject
- Actions